| Literature DB >> 11350195 |
Abstract
Topical application of podophyllin solution, long considered the therapy of first choice against condylomata acuminata, can no longer be recommended due to its low efficacy and gross toxicity. Self-treatment with 0.15-0.5% purified podophyllotoxin preparations, applied twice daily for 3 days, is now advocated as the alternative first-line therapy of choice, when significant improvement is conveniently, and cost-effectively, accomplished within a few weeks. This review provides a summary of the comparative efficacy and utility of podophyllin versus podophyllotoxin as well as a compilation of in vivo and in vitro safety evaluations. In light of overwhelming safety and efficacy data in favor of podophyllotoxin-derived products, it is concluded that podophyllin preparations have no place in the modern treatment portfolio for anogenital warts. Copyright 2001 Academic Press.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11350195 DOI: 10.1006/rtph.2000.1446
Source DB: PubMed Journal: Regul Toxicol Pharmacol ISSN: 0273-2300 Impact factor: 3.271